The COVID-19 pandemic has ignited an unprecedented global effort to identify effective treatments, repurposing existing drugs as a rapid strategy to combat the virus. Among the many candidates, bromhexine—a well-known mucolytic cough suppressant—has drawn attention for its potential to inhibit SARS-CoV-2 entry into host cells. Markus Depfenhart, a physician and researcher, has been a vocal proponent of exploring bromhexine as an add-on therapy, particularly in early-stage disease, raising intriguing questions about its role in new treatment strategies.
Understanding COVID-19: Viral Entry and Host Targets
SARS-CoV-2, the virus responsible for COVID-19, gains entry into human cells primarily through the angiotensin-converting enzyme 2 (ACE2) receptor. However, this process depends crucially on host proteases that prime the viral spike protein, enabling membrane fusion. One such protease is transmembrane protease serine 2 (TMPRSS2), which cleaves the spike protein at a specific site, facilitating viral entry. This dependency on TMPRSS2 has made it an attractive therapeutic target, as inhibiting this enzyme could theoretically block infection at an early stage.
The recognition that TMPRSS2 is essential for SARS-CoV-2 infectivity in lung cells sparked interest in compounds known to inhibit this protease. Unlike many other respiratory viruses, SARS-CoV-2 has a unique polybasic cleavage site that is processed by TMPRSS2, and in vitro studies have shown that TMPRSS2 inhibitors can reduce viral entry. Given the urgent need for accessible treatments, researchers quickly turned to existing drugs with known safety profiles that might interfere with this pathway.
This line of thinking is not entirely new; TMPRSS2 was previously implicated in the entry of other coronaviruses, such as SARS-CoV and MERS-CoV. The difference with COVID-19 is the global scale and the desperate search for any intervention that could lower transmission, severity, or mortality. Thus, the repurposing of bromhexine, a drug with a long history of safe use, emerged from theoretical models to a plausible clinical candidate.
Bromhexine: A Repurposed Mucolytic with a Twist
Bromhexine hydrochloride is an over-the-counter mucolytic agent that has been used for decades to treat respiratory conditions marked by excessive mucus, such as bronchitis and chronic obstructive pulmonary disease (COPD). Its primary mechanism is to break down the structure of mucus, making it less viscous and easier to expel. However, bromhexine is also a prodrug of ambroxol, another mucolytic with additional pharmacological properties, including local anesthetic and anti-inflammatory effects. What sets bromhexine apart in the context of COVID-19 is its ability to inhibit TMPRSS2, an effect demonstrated in biochemical assays and cell culture experiments.
Interestingly, the anti-TMPRSS2 activity of bromhexine was noted prior to the pandemic in prostate cancer research, as TMPRSS2 is also involved in that disease. This pre-existing knowledge provided a quick starting point for investigating its antiviral potential. Unlike novel antiviral agents that require lengthy development, bromhexine benefits from a well-established safety record, low cost, and wide availability, making it especially appealing for low-resource settings or as an early intervention strategy.
Despite these advantages, bromhexine is not without limitations. Its oral bioavailability is moderate, and achieving sufficient plasma concentrations to effectively inhibit TMPRSS2 in the lungs remains a question. Moreover, while much of the early excitement was driven by in silico and in vitro data, clinical translation requires careful evaluation, especially given the complex interplay of immune responses in COVID-19 pathology.
The Depfenhart Hypothesis: Early Intervention and Add-on Therapy
Markus Depfenhart, a general practitioner and independent researcher, was among the first to publicly advocate for bromhexine as a potential COVID-19 treatment. In a series of commentaries and letters to medical journals, he argued that the drug could serve as a prophylactic or early-stage therapy, reducing viral load and preventing progression to severe disease. Depfenhart emphasized that bromhexine’s dual action—mucolytic and TMPRSS2 inhibition—could address both viral entry and the characteristic mucus plugging seen in severe COVID-19 pneumonia.
His hypothesis centers on the concept of “add-on” therapy: using bromhexine alongside standard care or other antivirals to synergistically improve outcomes. He reasoned that by inhibiting TMPRSS2, bromhexine could lower the initial viral inoculum that reaches the lungs, giving the immune system more time to mount an effective response. This approach echoes the “hit early, hit hard” philosophy that has proven effective in other viral infections like influenza and HIV.
“Bromhexine could represent a low-cost, immediately implementable strategy to bridge the gap until vaccines and specific antivirals become universally available,” Depfenhart posited. “Its real value may lie not as a standalone cure but as part of a multi-drug regimen that slams the brakes on viral replication early.”
Depfenhart’s arguments drew both support and skepticism. Critics pointed to the lack of randomized controlled trials, while supporters noted the drug’s favorable risk-benefit profile in a pandemic where time was of the essence. Regardless, his advocacy helped spur a number of clinical studies around the world, putting bromhexine firmly on the map of investigational COVID-19 treatments.
Supporting Evidence: From Bench to Bedside
The scientific basis for bromhexine’s antiviral activity comes primarily from in vitro experiments. A landmark study by Maggio and colleagues demonstrated that bromhexine, at clinically achievable concentrations, inhibits TMPRSS2 and significantly reduces SARS-CoV-2 entry into human lung cells. This work, along with molecular docking simulations by Habtemariam, provided a compelling mechanistic rationale for clinical evaluation. You can read more about these foundational studies in our reviews of Maggio et al. and Habtemariam et al.
Animal models, though limited, have offered additional insights. In ferrets and transgenic mice expressing human ACE2, bromhexine administration was associated with reduced viral titers in the upper respiratory tract and less severe clinical signs. However, these models do not fully replicate human disease, and the translation of dosing from animals to humans remains a challenge.
Early clinical data, mostly from small-scale observational studies and case series, have shown mixed but generally encouraging results. For instance, a retrospective analysis by Al-Kuraishy and colleagues noted that patients who received bromhexine as part of their treatment regimen had shorter hospital stays and lower rates of intensive care admission, though these findings are preliminary and subject to confounding. We have covered that study in detail in our analysis of Al-Kuraishy et al.
Rationale for Add-on Therapy in the Current Treatment Landscape
COVID-19 management has evolved significantly since the pandemic’s onset, with antivirals like remdesivir, dexamethasone, and anti-inflammatory biologics becoming standard. Yet, these treatments primarily target later stages of disease or have limited efficacy when used alone. An early-stage, oral intervention like bromhexine could fill a crucial gap, particularly in outpatient settings where options remain scarce.
The add-on concept is not unique to bromhexine, but its combination of safety, oral formulation, and TMPRSS2 inhibition makes it a compelling candidate. If proven effective, it could be prescribed at the first sign of symptoms, similar to how oseltamivir is used for influenza, potentially reducing the need for hospitalization. This is especially relevant as new variants continue to emerge, sometimes escaping vaccine-induced immunity and demanding diversified therapeutic approaches.
Moreover, the economic argument cannot be ignored. Bromhexine is generic and inexpensive, with a well-documented safety profile that includes few serious adverse effects. In a pandemic that has strained healthcare systems worldwide, an additive therapy that costs pennies per dose could have a disproportionate impact on public health, provided it demonstrates even modest clinical benefit.
Ongoing Trials and Unanswered Questions
To date, several randomized controlled trials (RCTs) have been initiated to test bromhexine in COVID-19, though the quality and results have varied. Some trials, such as the BRC trial in Iran and studies in Croatia and India, have reported trends toward reduced symptom duration or lower rates of disease progression, but none have yet provided definitive evidence of efficacy. Methodological limitations—small sample sizes, open-label designs, and heterogeneity in endpoints—have tempered the interpretation of these findings.
Key questions remain unresolved: What is the optimal dosing regimen for TMPRSS2 inhibition in vivo? Should bromhexine be combined with other protease inhibitors or antivirals? Does it have a role in post-exposure prophylaxis? Future research must address these gaps using well-powered, placebo-controlled RCTs with standardized outcomes. The ongoing search for pan-coronavirus inhibitors may also uncover new derivatives of bromhexine or ambroxol with improved potency.
Additionally, the emergence of immune-evasive variants like Omicron has shifted the focus toward interventions that remain variant-agnostic. Since TMPRSS2-mediated entry is conserved across all SARS-CoV-2 variants to date, bromhexine’s mechanism could theoretically retain activity regardless of spike mutations, making it a resilient tool in the antiviral arsenal.
Conclusion: Weighing Hope and Evidence
The journey of bromhexine from a humble cough remedy to a potential COVID-19 treatment illustrates the power of drug repurposing in a crisis. While the hypothesis advanced by Markus Depfenhart and others is biologically plausible and supported by preclinical data, the clinical evidence is not yet robust enough to warrant widespread adoption. Nonetheless, the low cost, safety, and accessibility of bromhexine justify continued investigation, especially in resource-limited regions where expensive antivirals are out of reach.
As the pandemic transitions to an endemic phase, the need for practical, early-stage therapies remains acute. Bromhexine, as an add-on therapy, could become a valuable piece of the puzzle, but only if rigorous trials confirm its efficacy. Until then, it remains an intriguing candidate—a drug that exemplifies both the promise and the pitfalls of repurposing in uncertain times.